What is Fate Therapeutics Inc?
, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 111.82M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 16,582 shares $14k | 0 |
| 3-6months | 282,747 shares $204k | 0 |
| 6-9months | 254,536 shares $103k | 0 |
| 9-12months | 215,779 shares $17k | 0 |